Early Effects of Tumour Necrosis Factor Alpha Blockade on Skin and Synovial Tissue in Patients with Active Psoriasis and Psoriatic Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2004 Jun 15

PMID 15194570

Citations 32

Authors

A Y Goedkoop

M C Kraan

M B M Teunissen

D I Picavet

M A de Rie

J D Bos

P P Tak

Affiliations

Soon will be listed here.

Abstract

Background: Tumour necrosis factor alpha (TNFalpha) blockade using infliximab, a chimeric anti-TNFalpha antibody, is an effective treatment for both psoriasis and psoriatic arthritis (PsA).

Objective: To analyse the early effects of infliximab treatment on serial skin and synovial tissue biopsy samples.

Methods: Twelve patients with both active psoriasis and PsA received a single infusion of either infliximab (3 mg/kg) (n = 6) or placebo (n = 6) intravenously. Synovial tissue and lesional skin biopsy specimens were obtained at baseline and 48 hours after treatment. Immunohistochemical analysis was performed to analyse the inflammatory infiltrate. In situ detection of apoptotic cells was performed by TUNEL assay and by immunohistochemical staining with anti-caspase-3 antibodies. Stained tissue sections were evaluated by digital image analysis.

Results: A significant reduction in mean (SEM) T cell numbers was found in both lesional epidermis (baseline 37 (11) cells/mm, 48 hours 26 (11), p = 0.028) and synovial tissue (67 (56) cells/mm(2)v 32 (30), p = 0.043) after infliximab treatment, but not after placebo treatment (epidermis 18 (8) v 43 (20), NS; synovium 110 (62) v 46 (21), NS). Similarly, the number of macrophages in the synovial sublining was significantly reduced after anti-TNFalpha treatment (100 (73) v 10 (8), p = 0.043). The changes in cell numbers could not be explained by induction of apoptosis at the site of inflammation.

Conclusions: The effects of anti-TNFalpha therapy in psoriasis and psoriatic arthritis may be explained by decreased cell infiltration in lesional skin and inflamed synovial tissue early after initiation of treatment.

Citing Articles

Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

Cagnotto G, Bruschettini M, Strozyk A, Scire C, Compagno M Cochrane Database Syst Rev. 2025; 2:CD013614.

PMID: 39945386 PMC: 11822884. DOI: 10.1002/14651858.CD013614.pub2.

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis.

Ciliento M, Venturelli V, Schettini N, Bertola R, Garaffoni C, Lanza G Int J Mol Sci. 2023; 24(5).

PMID: 36902437 PMC: 10002880. DOI: 10.3390/ijms24055006.

Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.

Najm A, Goodyear C, McInnes I, Siebert S Nat Rev Rheumatol. 2023; 19(3):153-165.

PMID: 36596924 DOI: 10.1038/s41584-022-00874-5.

Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.

Hawerkamp H, Fahy C, Fallon P, Schwartz C Skin Health Dis. 2022; 2(2):e99.

PMID: 35677926 PMC: 9168024. DOI: 10.1002/ski2.99.

Translational Research Studies Unraveling the Origins of Psoriatic Arthritis: Moving Beyond Skin and Joints.

Bolt J, van Ansenwoude C, Hammoura I, van de Sande M, van Baarsen L Front Med (Lausanne). 2021; 8:711823.

PMID: 34485340 PMC: 8415974. DOI: 10.3389/fmed.2021.711823.

References

Reece R, Canete J, Parsons W, Emery P, Veale D . Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999; 42(7):1481-4. DOI: 10.1002/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E. View

Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, van Hogezand R . Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340(18):1398-405. DOI: 10.1056/NEJM199905063401804. View

Taylor P, Peters A, Paleolog E, Chapman P, Elliott M, McCloskey R . Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43(1):38-47. DOI: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. View

Kraan M, Haringman J, Ahern M, Breedveld F, Smith M, Tak P . Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford). 2000; 39(1):43-9. DOI: 10.1093/rheumatology/39.1.43. View

Oh C, Das K, Gottlieb A . Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000; 42(5 Pt 1):829-30. DOI: 10.1067/mjd.2000.105948. View

Mease P, GOFFE B, Metz J, VanderStoep A, Finck B, Burge D . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227):385-90. DOI: 10.1016/S0140-6736(00)02530-7. View

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C . Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001; 44(1):186-95. DOI: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B. View

Costello P, Winchester R, Curran S, Peterson K, Kane D, Bresnihan B . Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001; 166(4):2878-86. DOI: 10.4049/jimmunol.166.4.2878. View

10.

OGILVIE A, Antoni C, Dechant C, Manger B, Kalden J, Schuler G . Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001; 144(3):587-9. DOI: 10.1046/j.1365-2133.2001.04089.x. View

11.

Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A . Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001; 357(9271):1842-7. DOI: 10.1016/s0140-6736(00)04954-0. View

12.

Ellis C, Krueger G . Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001; 345(4):248-55. DOI: 10.1056/NEJM200107263450403. View

13.

Sandborn W, Hanauer S, Katz S, Safdi M, Wolf D, BAERG R . Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121(5):1088-94. DOI: 10.1053/gast.2001.28674. View

14.

Ten Hove T, van Montfrans C, Peppelenbosch M, van Deventer S . Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002; 50(2):206-11. PMC: 1773100. DOI: 10.1136/gut.50.2.206. View

15.

Wollina U, Konrad H . Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol. 2002; 16(2):127-9. DOI: 10.1046/j.1468-3083.2002.00391.x. View

16.

Kraan M, Reece R, Smeets T, Veale D, Emery P, Tak P . Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum. 2002; 46(8):2034-8. DOI: 10.1002/art.10556. View

17.

Antoni C, Dechant C, Wendler J, Ogilvie A, Lueftl M, Kalden J . Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002; 47(5):506-12. DOI: 10.1002/art.10671. View

18.

Kraan M, van Kuijk A, Dinant H, Goedkoop A, Smeets T, de Rie M . Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002; 46(10):2776-84. DOI: 10.1002/art.10543. View

19.

Gottlieb A, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U . Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003; 48(1):68-75. DOI: 10.1067/mjd.2003.10. View

20.

van den Brande J, Braat H, van den Brink G, Versteeg H, Bauer C, Hoedemaeker I . Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124(7):1774-85. DOI: 10.1016/s0016-5085(03)00382-2. View